1. Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo
- Author
-
Alexey Koval a, 1, Ivan Bassanini b, k, Jiabin Xu a, c, Michele Tonelli d, Vito Boido d, Fabio Sparatore d, Frederic Amant e, f, g, Daniela Annibali e, Eleonora Leucci h, i, Anna Sparatore b, 2, Vladimir L. Katanaev a, j, Obstetrics and Gynaecology, CCA - Cancer biology and immunology, and Amsterdam Reproduction & Development (AR&D)
- Subjects
medicine.medical_treatment ,Chemistry, Medicinal ,Medicinal chemistry ,Mice, SCID ,01 natural sciences ,Clofazimine ,Targeted therapy ,Mice ,Riminophenazine ,Mice, Inbred NOD ,Drug Discovery ,Pharmacology & Pharmacy ,DRUG ,Wnt signaling Triple-negative breast cancer Clofazimine Riminophenazine Medicinal chemistry Patient-derived xenograf ,Wnt Signaling Pathway ,Triple-negative breast cancer ,0303 health sciences ,Molecular Structure ,Chemistry ,DERIVATIVES ,Wnt signaling pathway ,General Medicine ,Life Sciences & Biomedicine ,medicine.drug ,Patient-derived xenograft ,Wnt signaling ,Structure-Activity Relationship ,03 medical and health sciences ,In vivo ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Potency ,ddc:612 ,Cell Proliferation ,030304 developmental biology ,Pharmacology ,Science & Technology ,Dose-Response Relationship, Drug ,010405 organic chemistry ,Organic Chemistry ,Mammary Neoplasms, Experimental ,Water ,Cancer ,medicine.disease ,In vitro ,0104 chemical sciences ,PHENAZINES ,Solubility ,Cancer research ,Phenazines ,Drug Screening Assays, Antitumor - Abstract
Triple-negative breast cancer (TNBC) is a cancer subtype critically dependent upon excessive activation of Wnt pathway. The anti-mycobacterial drug clofazimine is an efficient inhibitor of canonical Wnt signaling in TNBC, reducing tumor cell proliferation in vitro and in animal models. These properties make clofazimine a candidate to become first targeted therapy against TNBC. In this work, we optimized the clofazimine structure to enhance its water solubility and potency as a Wnt inhibitor. After extensive structure-activity relationships investigations, the riminophenazine 5-(4-(chlorophenyl)-3-((2-(piperazin-1-yl)ethyl)imino)-N-(pyridin-3-yl)-3,5-dihydrophenazin-2-amine (MU17) was identified as the new lead compound for the riminophenazine-based targeted therapy against TNBC and Wnt-dependent cancers. Compared to clofazimine, the water-soluble MU17 displayed a 7-fold improved potency against Wnt signaling in TNBC cells resulting in on-target suppression of tumor growth in a patient-derived mouse model of TNBC. Moreover, allowing the administration of reduced yet effective dosages, MU17 displayed no adverse effects, most notably no clofazimine-related skin coloration. ispartof: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY vol:222 ispartof: location:France status: published
- Published
- 2021